Suchergebnisse
Biomarker innovations. The main mortality drivers in intensive care units are diagnostic blind spots. We pave the way for early intervention and personalized medicine in acute and critical care with innovative biomarkers. Read more.
- Products
The microtiter plate is a standard tool in analytical...
- Science
Sometimes, in critically ill patients, the underlying...
- Collaboration
SphingoTec develops and markets innovative biomarkers for...
- Company
SphingoTec develops and markets innovative in vitro...
- Resource Center
About us . SphingoTec GmbH develops innovative biomarkers...
- Blog
Current applications of precision medicine in intensive care...
- Products
The latest posts from @sphingotec
SphingoTec GmbH develops innovative biomarkers for diagnosis, prediction and monitoring of acute medical conditions, such as acute heart failure, acute kidney injury and circulatory shock, in...
18. Juni 2024 · 09. May 2023. SphingoTec's Innovative IVD Product sphingotest® penKid® Receives First IVDR Certificate. SphingoTec has been successfully re-certified according to ISO 13485 and received its first IVDR certificate for its IVD product sphingotest® penKid®.
SphingoTec develops and markets innovative in vitro diagnostics solutions for novel and proprietary blood-based protein biomarkers. Our aspiration is to effectively translate scientific advancements into routine clinical practice.
Pressemitteilung Beteiligungsunternehmen Sphingotec GmbH. Hennigsdorf/Berlin, Deutschland, 11 April 2022 – Das Diagnostikunternehmen SphingoTec GmbH (SphingoTec) gibt die Anwendung von zwei Biomarkern zur Steuerung eines neuen Covid-19 Medikamentenkandidats bekannt.
8. Aug. 2022 · Biomarker von der Forschung bis zur klinischen Praxis. Akute Nierenschädigung (AKI) betrifft 1 von 3 Intensivpatienten. Da die therapeutischen Möglichkeiten begrenzt sind, liegt der Fokus auf der Behandlung der Symptome und der Vermeidung des Fortschreitens von AKI.
